In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and application of artificial intelligence into care.

Video version: https://www.hcplive.com/view/diabetes-dialogue-hot-topics-and-updates-from-attd-2024 

In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health.

During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmacotherapies has altered conversations around management, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-flow-trial-and-chronic-kidney-disease-updates-with-brendon-neuen-mbbs-phd

00:32 - Neuen Introduction

01:55 - FLOW Trial

05:15 - Pillars of CKD Therapy

16:15 - Need for New Guidelines

21:15 - Barriers to Uptake

24:50 - Need for Screening

Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach discussed the ongoing global rollout of the Dexcom G7 and how he expected expanded coverage of the device to open doors to greater personalization of care for people with diabetes.

In the current episode, Leach and hosts touch upon the Stelo clearance, its accuracy relative to other CGM devices, plans for rollout and pricing, the importance of increased accessibility of CGM technology, and the push for greater accuracy in glucose monitoring devices.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-stelo-news-and-dexcom-cgm-updates-with-jake-leach

00:30 - Jake Leach Introduction

01:20 - Dexcom Stelo Overview

06:25 - Differences vs G6 and G7

 14:45 - Direct to Watch Technology

20:05 - Future of Dexcom Portfolio

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Key Timestamps

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies.

00:35 - Guest Introduction

01:10 - SELECT Results Overview

04:25 - Next Steps for Research

07:15 - Mechanism of Action for CV Benefit

09:00 - FLOW Trial Implications

11:25 - Impact on Access

15:00 - Future of Incretin Therapies

21:45 - Predicting the Next 5-10 Years for Semaglutide

In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.

Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors

Key Highlights:

00:35 - The Myth of MARD

04:10 - Considerations When Interpreting MARD

10:15 - FreeStyle Libre 3 vs. Dexcom G7

In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview 

Key Highlights: 

01:05 - Bellini’s ATTD Picks

03:45 - Isaacs’ ATTD Picks

06:20 - Health Disparities in Focus

07:10 - Time in Tighter Range

10:20 - Insulin Users with T2D

11:15 - ATTD Yearbook Session

The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes.

In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and other advanced CGM metrics with diabetic retinopathy and the implications for use in predicting other microvascular outcomes.

00:05 - Intro

02:04 - CGM Data to Predict Diabetes Complications

05:15 - Time in Range and Microvascular Complications

09:36 - Glycemic Variability and Incident Diabetic Retinopathy

12:17 - Time in Range, CGM Data for Predicting CV Outcomes

In this episode, hosts are joined by Shah for a discussion on his recent proof-of-concept study looking at tirzepatide in type 1 diabetes, the prospect of GLP-1 RA-based therapies in type 1 diabetes, and the potential roles for tirzepatide beyond T2D and weight management.

00:00 - Intro

01:56 - Use of GLP-1s in T1D

05:32 - Study on Tirzepatide in T1D 

10:04 - Insulin Use in Study

11:20 - Safety Outcomes